Shots:

• The P-III YOSEMITE & RHINE studies assessing faricimab vs aflibercept in 1891 people living with DME. The studies include 3 treatment arms: faricimab (6mg) administered at personalized dosing intervals of ~16wks and at fixed 8wks. intervals & aflibercept (2mg) at fixed 8wks. intervals
• The studies met its 1EPs i.e faricimab in both the doses demonstrated non-inferior visual acuity gains compared to aflibercept and was well tolerated with no new safety signals identified
• Faricimab is the first investigational bispecific Ab targeting 2 distinct pathways i.e.- Ang-2 and VEGF-A- currently being evaluated in P-III TENAYA and LUCERNE studies for nAMD

 ­ Ref: GlobeNewswire  | Image: Roche